Factor VIII activation by factor VIIa analog (V158D/E296V/M298Q) in tissue factor-independent mechanisms

Thrombosis and Haemostasis

Volumn 106, Issue 4, 2011, Pages 665-674

  Ogiwara, Kenichi ^a   Nogami, Keiji ^a   Shima, Midori ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Activation; Cleavage; Factor viia analog; Factor VIII(a); Tissue factor

Indexed keywords

ARGININE; BLOOD CLOTTING FACTOR 8; NN 1731; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BLOOD CLOTTING FACTOR ACTIVATION; BLOOD CLOTTING PARAMETERS; CONTROLLED STUDY; DRUG PROTEIN BINDING; HEMOSTASIS; HUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DOMAIN; UPREGULATION;

BLOOD COAGULATION; CATALYSIS; CATALYTIC DOMAIN; CLICK CHEMISTRY; FACTOR VII; FACTOR VIIA; FACTOR VIII; HEMOSTASIS; HUMANS; PROTEIN ENGINEERING; PROTEOLYSIS; THROMBIN; THROMBOPLASTIN;

EID: 80053209848     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-04-0264     Document Type: Article

References (34)

1. Mann KG, Nesheim ME, Church WR, et al. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990; 76: 1-16.
2. Wood WI, Capon DJ, Simonsen CC, et al. Expression of active human factor VIII from recombinant DNA clones. Nature 1984; 312: 330-337.
3. Eaton D, Rodriguez H, Vehar GA. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 1986; 25: 505-512.
4. Fay PJ. Activation of factor VIII and mechanisms of cofactor action. Blood Rev 2004; 18: 1-15.
5. Fay PJ, Mastri M, Koszelak ME, et al. Cleavage of factor VIII heavy chain is required for the functional interaction of A2 subunit with factor IXa. J Biol Chem 2001; 276: 12434-12439.
6. Lollar P, Hill-Eubanks DC, Parker CG. Association of the factor VIII light chain with von Willebrand factor. J Biol Chem 1988; 263: 10451-10455.
7. Nogami K, Wakabayashi H, Schmidt K, et al. Altered interactions between the A1 and A2 subunits of factor VIIIa following cleavage of A1 subunit by factor Xa. J Biol Chem 2003; 278: 1634-1641.
8. Komiyama Y, Pedersen AH, Kisiel W. Proteolytic activation of human factors IX and X by recombinant human factor VIIa: effects of calcium, phospholipids, and tissue factor. Biochemistry 1990; 29: 9418-9425.
9. Hoffman M. Remodeling the blood coagulation cascade. J Thromb Thrombolysis 2003; 16: 17-20.
10. Mann KG, Krishnaswamy S, Lawson JH. Surface-dependent hemostasis. Semin Hematol 1992; 29: 213-226.
11. Soeda T, Nogami K, Matsumoto T, et al. Mechanisms of factor VIIa-catalyzed activation of factor VIII. J Thromb Haemost 2010; 8: 2494-2503.
12. Newell JL, Fay PJ. Cleavage at Arg1689 influences heavy chain cleavages during thrombin-catalyzed activation of factor VIII. J Biol Chem 2009; 284: 11080-11089.
13. Gabriel DA, Li X, Monroe DM 3rd, et al. Recombinant human factor VIIa (rFVIIa) can activate factor FIX on activated platelets. J Thromb Haemost 2004; 2: 1816-1822.
14. Hedner U. Mechanism of action, development and clinical experience of recombinant FVIIa. J Biotechnol 2006; 124: 747-757.
15. Monroe D, Hoffman M, Oliver J, et al. Platelet activity of high-dose factor VIIa in independent of tissue factor. Br J Haematol 1997; 99: 542-547.
16. Brophy DF, Martin EJ, Nolte ME, et al. Effect of recombinant factor VIIa variant (NN1731) on platelet function, clot structure and force onset time in whole blood from healthy volunteers and haemophilia patients. Haemophilia 2007; 13: 533-541.
17. Persson E, Kjalke M, Olsen OH. Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity. Proc Natl Acad Sci USA 2001; 98: 13583-13588.
18. Allen GA, Persson E, Campbell A, et al. A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia. Arterioscler Thromb Vasc Biol 2007; 27: 683-689.
19. Holmberg HL, Lauritzen B, Tranholm M, et al. Faster onset of effect and greater efficacy of NN1731 compared with rFVIIa, aPCC and FVIII in tail bleeding in hemophilic mice. J Thromb Haemost 2009; 7: 1517-1522.
20. Sorensen B, Persson E, Ingerslev J. Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A. Br J Haematol 2007; 137: 158-165.
21. Nogami K, Nishiya K, Saenko EL, et al. Identification of a plasmin-interactive site within the A2 domain of the factor VIII heavy chain. Biochim Biophys Acta 2008; 1784: 753-763.
22. Pipe SW, Kaufman RJ. Characterization of a genetically engineered inactivationresistant coagulation factor VIIIa. Proc Natl Acad Sci USA 1997; 94: 11851-11856.
23. Takeshima K, Smith C, Tait J, et al. The preparation and phospholipid binding property of the C2 domain of human factor VIII. Thromb Haemost 2003; 89: 88-94.
24. Shima M, Scandella D, Yoshioka A, et al. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost 1993; 69: 240-246.
25. Foster PA, Fulcher CA, Houghten RA, et al. Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine351-serine365 of the factor VIII heavy chain. J Clin Invest 1998; 82: 123-128.
26. Mimms LT, Zampighi G, Nozaki Y, et al. Phospholipid vesicle formation and transmembrane protein incorporation using octyl glucoside. Biochemistry 1981; 20: 833-840.
27. Warren DL, Morrissey JH, Neuenschwander PF. Proteolysis of blood coagulation factor VIII by the factor VIIa-tissue factor complex: generation of an inactive factor VIII cofactor. Biochemistry 1999; 38: 6529-6536.
28. Sorensen BB, Persson E, Freskgârd PO, et al. Incorporation of an active site inhibitor in factor VIIa alters the affinity for tissue factor. J Biol Chem 1997; 272: 11863-11868.
29. Jesty J, Wun TC, Lorenz A. Kinetics of the inhibition of factor Xa and the tissue factor-factor VIIa complex by the tissue factor pathway inhibitor in the presence and absence of heparin. Biochemistry 1994; 33: 12686-12694.
30. van 't Veer C, Hackeng TM, Delahaye C, et al. Activated factor X and thrombin formation triggered by tissue factor on endothelial cell matrix in a flow model: effect of the tissue factor pathway inhibitor. Blood 1994; 84: 1132-1142.
31. Berntorp E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia 2009; 15: 3-10.
32. Kasuda S, Tanaka I, Shima M, et al. Effectiveness of factor VIII infusions in haemophilia A patients with high responding inhibitors. Haemophilia 2004; 10: 341-346.
33. Meeks SL, Healey JF, Parker ET, et al. Anti-human factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation. Blood 2007; 110: 4234-4242.
34. Yada K, Nogami K, Ogiwara K, et al. Effects of anti-factor VIII inhibitor antibodies on factor VIIa/tissue factor-catalyzed activation and inactivation of factor VIII. Thromb Haemost 2011; 106: 989-998.